BASTIDE LE CONFORT MEDICAL (BLC.PA) Fundamental Analysis & Valuation

EPA:BLC • FR0000035370

Current stock price

24.6 EUR
-0.3 (-1.2%)
Last:

This BLC.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BLC.PA Profitability Analysis

1.1 Basic Checks

  • In the past year BLC was profitable.
  • BLC had a positive operating cash flow in the past year.
  • BLC had positive earnings in 4 of the past 5 years.
  • In the past 5 years BLC always reported a positive cash flow from operatings.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • With an excellent Return On Assets value of 5.07%, BLC belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
  • With an excellent Return On Equity value of 28.66%, BLC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • BLC has a Return On Invested Capital of 6.83%. This is in the better half of the industry: BLC outperforms 78.57% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 6.23%.
  • The last Return On Invested Capital (6.83%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROIC 6.83%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • BLC's Profit Margin of 6.19% is amongst the best of the industry. BLC outperforms 92.86% of its industry peers.
  • BLC's Profit Margin has declined in the last couple of years.
  • BLC has a Operating Margin of 8.05%. This is in the better half of the industry: BLC outperforms 67.86% of its industry peers.
  • In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
  • BLC has a Gross Margin of 67.32%. This is in the better half of the industry: BLC outperforms 75.00% of its industry peers.
  • BLC's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BLC.PA Health Analysis

2.1 Basic Checks

  • BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, BLC has about the same amount of shares outstanding.
  • Compared to 5 years ago, BLC has about the same amount of shares outstanding.
  • BLC has a better debt/assets ratio than last year.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.54, we must say that BLC is in the distress zone and has some risk of bankruptcy.
  • BLC has a Altman-Z score of 1.54. This is comparable to the rest of the industry: BLC outperforms 46.43% of its industry peers.
  • BLC has a debt to FCF ratio of 14.03. This is a negative value and a sign of low solvency as BLC would need 14.03 years to pay back of all of its debts.
  • BLC has a worse Debt to FCF ratio (14.03) than 64.29% of its industry peers.
  • BLC has a Debt/Equity ratio of 2.95. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of BLC (2.95) is worse than 78.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Altman-Z 1.54
ROIC/WACC1.31
WACC5.2%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • BLC has a Current Ratio of 1.16. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • BLC has a Current ratio (1.16) which is in line with its industry peers.
  • A Quick Ratio of 0.92 indicates that BLC may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.92, BLC is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.92
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLC.PA Growth Analysis

3.1 Past

  • BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1718.18%, which is quite impressive.
  • The earnings per share for BLC have been decreasing by -46.37% on average. This is quite bad
  • BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 0.77%.
  • Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.90% on average over the next years.
  • The Revenue is expected to grow by 7.69% on average over the next years.
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

6

4. BLC.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • BLC is valuated cheaply with a Price/Earnings ratio of 6.15.
  • Based on the Price/Earnings ratio, BLC is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.42, BLC is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 12.00, the valuation of BLC can be described as correct.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BLC indicates a somewhat cheap valuation: BLC is cheaper than 67.86% of the companies listed in the same industry.
  • BLC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.24, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6.15
Fwd PE 12
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 92.86% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BLC is valued a bit cheaper than 64.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.85
EV/EBITDA 4.95
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The decent profitability rating of BLC may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.23%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLC.PA Dividend Analysis

5.1 Amount

  • No dividends for BLC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLC.PA Fundamentals: All Metrics, Ratios and Statistics

BASTIDE LE CONFORT MEDICAL

EPA:BLC (4/24/2026, 7:00:00 PM)

24.6

-0.3 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-18
Earnings (Next)05-14
Inst Owners12.78%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap181.30M
Revenue(TTM)476.02M
Net Income(TTM)29.45M
Analysts77.14
Price Target40.8 (65.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP0.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.68%
PT rev (3m)12.68%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-8.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 6.15
Fwd PE 12
P/S 0.38
P/FCF 7.85
P/OCF 2.51
P/B 1.76
P/tB N/A
EV/EBITDA 4.95
EPS(TTM)4
EY16.26%
EPS(NY)2.05
Fwd EY8.33%
FCF(TTM)3.13
FCFY12.74%
OCF(TTM)9.79
OCFY39.8%
SpS64.59
BVpS13.94
TBVpS-12.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.4217 (43.99%)
Profitability
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROCE 9.29%
ROIC 6.83%
ROICexc 7.28%
ROICexgc 14.48%
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
FCFM 4.85%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Debt/EBITDA 3.11
Cap/Depr 83.01%
Cap/Sales 10.3%
Interest Coverage 250
Cash Conversion 74.08%
Profit Quality 78.46%
Current Ratio 1.16
Quick Ratio 0.92
Altman-Z 1.54
F-Score7
WACC5.2%
ROIC/WACC1.31
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%
EBIT growth 1Y3.06%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year138.04%
EBIT Next 3Y38.82%
EBIT Next 5YN/A
FCF growth 1Y-31.71%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y-17.98%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 5 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 6 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.


What is the profitability of BLC stock?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for BLC stock?

The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 6.15 and the Price/Book (PB) ratio is 1.76.


Can you provide the financial health for BLC stock?

The financial health rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 3 / 10.